胰腺腺癌(PAAD)是一种常见的高度恶性的胃肠道肿瘤。因此,探索PAAD的耐药机制和免疫通路对临床治疗至关重要。在这项研究中,在正常和PAAD样本之间总共鉴定出497个差异表达基因(DEGs),并富集到117个GO术语和7个功能通路。随后,5个总生存相关DEGs(ESRP1,KRT6A,H2BC11,H2BC4和KLK)使用TCGA数据集中的Cox危害回归分析生成。此外,加权基因共表达网络分析显示,在5个生存相关的DEGs中,ESRP1和PAAD之间有很强的相关性.根据ESRP1表达水平将患者分为两组,通过单样本基因集富集分析,低ESRP1表达比高ESRP1表达存在更强的免疫浸润和更高的免疫调节靶标表达,这表明与高ESRP1表达相比,低ESRP1表达与更长的生存期相关。最后,我们的研究还发现,GEO数据集中的免疫细胞分布和免疫调节靶基因表达与TCGA队列相似.总的来说,我们的研究结果表明,通过整合来自各种数据库的数据,ESRP1可能在影响PAAD患者的免疫环境和调节免疫功能方面发挥作用.重要意义:利用TCGA和GEO数据集,本研究揭示了上皮剪接调节蛋白1(ESRP1)对PAAD的显著影响。ESRP1作为免疫功能的关键调节因子,影响肿瘤微环境和免疫细胞浸润。聚类分析显示低ESRP1表达与增强的免疫活性相关。预测更好的预后。这一发现表明ESRP1可以作为PAAD预后的潜在生物标志物。通过影响免疫调节和肿瘤进展,为个性化免疫治疗提供新的见解。
Pancreatic adenocarcinoma (PAAD) is a prevalent and highly malignant gastrointestinal tumor. Therefore, exploring the mechanisms of drug resistance and immune pathways in PAAD is crucial for clinical treatment. In this study, a total of 497 differentially expressed genes (DEGs) were identified between normal and PAAD samples, and which were enriched to 117 GO terms and 7 functional pathways. Subsequently, 5 overall survival-related DEGs (
ESRP1, KRT6A, H2BC11, H2BC4 and KLK) was generated using Cox hazards regression analysis in TCGA dataset. Furthermore, the weighted gene co-expression network analysis revealed a strong association between
ESRP1 and PAAD among 5 survival-related DEGs. Patients were divided into two clusters based on
ESRP1 expression levels, and low
ESRP1 expression existed stronger immune infiltration and higher expression of immunomodulatory targets than high ESRP1 expression by single-sample gene set enrichment analysis, which indicated that low ESRP1 expression was associated with longer survival compared to high
ESRP1 expression. Finally, our study also found that immune cells distribution and immunomodulatory targets gene expression in the GEO dataset were similar to the TCGA cohort. Overall, our findings suggest that ESRP1 may play a role in influencing immune contexture and regulating immune function of PAAD patients by integrating data from various databases. SIGNIFICANCE: Utilizing TCGA and GEO datasets, this study uncovers the significant impact of epithelial splicing regulatory protein 1 (ESRP1) on PAAD. ESRP1 emerges as a key regulator of immune function, influencing tumor microenvironment and immune cell infiltration. Cluster analysis shows that low
ESRP1 expression correlates with enhanced immune activity, predicting better prognosis. This discovery suggests that ESRP1 can serve as a potential biomarker for the prognosis of PAAD, offering new insights into personalized immunotherapy by influencing immune regulation and tumor progression.